Get in touchPrescribing informationAE reporting
Prescribing informationAE reporting
HomeNeuroblastoma and the unmet needIndicationHeritage
The QARZIBA® story
Neuroblastoma and the unmet needIndicationHeritage
How QARZIBA® works
How immunotherapy worksQARZIBA®'s mechanism of action
How immunotherapy worksQARZIBA®'s mechanism of action
QARZIBA® efficacy and safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
QARZIBA® efficacy dataQARZIBA® safety profile
Resources
Infusion & administrationDosing calculator
Infusion & administrationDosing calculatorGet in touchPrescribing Information
Terms of usePrivacy policyCookie policyContact
Home
How QARZIBA® works
Mechanism of action

Mechanism of action

QARZIBA® is a chimeric monoclonal IgG1 antibody that targets disialoganglioside 2 (GD2), a marker that is overexpressed on neuroblastoma cells. QARZIBA® then harnesses the immune system to target a patient’s neuroblastoma cells through two main mechanisms:1-3

Antibody-dependent cell-mediated cytotoxicity (ADCC)1-3

Natural killer (NK) cells and granulocytes recognise QARZIBA® bound to tumour cells and release cytotoxic granules and cytokines that cause tumour cell death.

Complement-dependent cytotoxicity (CDC)1-3

Binding of C1q (a protein complex) to tumour-bound QARZIBA® activates the complement cascade. This activation causes the formation of membrane attack complexes which create pores in the targeted cell membrane, causing cell lysis and death.

To learn more about neuroblastoma and the mechanism of action of QARZIBA®, watch our video!

Other pages in this section

How immunotherapy works

jamie-staff

GL-DNB-2200037 | December 2022

References

  1. Sait S and Modak SI. Expert Rev Anticancer Ther 2017; 17 (10): 889–904.
  2. Keyel ME and Reynolds CP. Biologics 2019; 13: 1–12.
  3. QARZIBA® (dinutuximab beta). Summary of product characteristics.

This is a promotional website created by Recordati Rare Diseases and is intended for HCPs only.